Dbv technologies announces financing of up to $306.9 million (€284.5 million) to advance viaskin® peanut patch through biologics license application submission and u.s. commercial launch, if approved

ChÂtillon, france, march 27, 2025 dbv technologies announces financing of up to $306.9 million (€284.5 million) to advance viaskin® peanut patch through biologics license application submission and u.s. commercial launch, if approved dbv secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrants dbv sufficiently funded through the expected biologics license application (bla) submission to food and drug administration (fda) for the viaskin® peanut patch in children 4 – 7-years-old and commercial launch, if approved dbv will host an investor conference call on monday, march 31 st at 5:00pm et (23h00 cet) to discuss the financing and fda update dbv technologies (the “company” or “dbv”) (euronext: dbv – isin: fr0010417345 – nasdaq capital market: dbvt), a clinical-stage biopharmaceutical company dedicated to treating pediatric allergies, today announced a financing of up to $306.9 million (€284.5 million), including gross proceeds of $125.5 million (€116.3 million) to be received upon closing and an aggregate of up to ($181.4 million) (€168.2 million) in gross proceeds if all the warrants are exercised, subject to satisfaction of specified conditions. the vitesse phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of some of the warrants.
DBVT Ratings Summary
DBVT Quant Ranking